Deposition of beta amyloid in senile plaques and the cerebral vasculature is a well-known, but poorly understood feature of Alzheimer's disease. The recent demonstration of a neurotoxic fragment of the amyloid precursor protein suggests that amyloid may be directly involved in the pathogenesis of Alzheimer's disease (Yankner et al., 1989). This proposal involves the use of protein biochemistry, neuronal cell culture and neuropathology to elucidate the normal and pathological functions of amyloid in the nervous system. Neurotoxic amyloid proteins will be purified from the conditioned medium of cDNA-transfected cells by immunoaffinity chromatography and HPLC. Polypeptide structure-function analysis of the neurotoxic amyloid protein will involve sequencing of the purified protein(s) and the testing of synthetic amyloid peptides. The presence of amyloid neurotoxic protein in the Alzheimer's disease brain will be determined by using methods of isolation optimized on the in vitro culture system. Purified neurotoxic amyloid protein will be added to primary neuronal cultures and introduced into the rodent CNS in vivo to determine if the distribution of neuronal degeneration parallels that observed in Alzheimer's disease. The mechanism of amyloid neurotoxicity will be examined in cell culture and specific pharmacologic maneuvers to block the toxicity will be tested. The normal biological function of the amyloid precursor protein (APP) in the central nervous system is unknown. Based on preliminary observations of increased neurite outgrowth in APP-transfected cells, two forms of the amyloid precursor protein (APP) will be purified and tested for neurotrophic effects in culture and in the rodent CNS in vivo. A newly developed tissue section bioassay will be utilized to assay the effects of endogenous APP and amyloid in the rodent and human CNS. The normal patterns of APP expression will be determined in culture and in the developing rodent CNS by Western blot analysis using antibodies which can distinguish between the two forms of the APP. This multidisciplinary approach is likely to yield substantial information on the issue of amyloid biological function and has potential clinical application in helping to design therapeutic strategies for Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29AG009229-02
Application #
3453457
Study Section
Neurology B Subcommittee 2 (NEUB)
Project Start
1990-08-01
Project End
1995-07-31
Budget Start
1991-08-01
Budget End
1992-07-31
Support Year
2
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Busciglio, J; Lorenzo, A; Yeh, J et al. (1995) beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14:879-88
Martin, B L; Schrader-Fischer, G; Busciglio, J et al. (1995) Intracellular accumulation of beta-amyloid in cells expressing the Swedish mutant amyloid precursor protein. J Biol Chem 270:26727-30
Lorenzo, A; Yankner, B A (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A 91:12243-7
Gabuzda, D; Busciglio, J; Chen, L B et al. (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269:13623-8
Busciglio, J; Gabuzda, D H; Matsudaira, P et al. (1993) Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A 90:2092-6
Gabuzda, D; Busciglio, J; Yankner, B A (1993) Inhibition of beta-amyloid production by activation of protein kinase C. J Neurochem 61:2326-9
Busciglio, J; Yeh, J; Yankner, B A (1993) beta-Amyloid neurotoxicity in human cortical culture is not mediated by excitotoxins. J Neurochem 61:1565-8
Kowall, N W; McKee, A C; Yankner, B A et al. (1992) In vivo neurotoxicity of beta-amyloid [beta(1-40)] and the beta(25-35) fragment. Neurobiol Aging 13:537-42
Chen, M; Tempst, P; Yankner, B A (1992) Secretogranin I/chromogranin B is a heparin-binding adhesive protein. J Neurochem 58:1691-8
Kowall, N W; Beal, M F; Busciglio, J et al. (1991) An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci U S A 88:7247-51

Showing the most recent 10 out of 13 publications